Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oleylphosphocholine in Healthy Adults
NCT06124144Phase 1Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oleylphosphocholine in leishmaniasis, sponsored by University Hospital Tübingen. Primary endpoint: Treatment-emergent adverse events at 35 days. Started Jun 2023; status: terminated.
02
Drugs
Oleylphosphocholine
03
Conditions
leishmaniasis
Beyond the preview
Go deeper on NCT06124144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124144.